Advanced Nanosystems and Emerging Therapies: Innovations in Tuberculosis Treatment and Drug Resistance

Tuberculosis (TB) remains a significant worldwide health challenge due to the limitations of conventional treatments and the rising incidence of drug-resistant Mycobacterium tuberculosis strains. This review consolidates the advancements in nanotechnology-based therapeutics, inhalable formulations, CRISPR–Cas tools, host-directed therapies (HDTs), and nanoparticle-based vaccine development aimed at enhancing TB management. Novel nanocarriers such as liposomes, solid-lipid nanoparticles (SLNs), dendrimers, and polymeric nanoparticles (NPs) offer enhanced bioavailability of drugs, sustained release, as well as targeted delivery to infected macrophages, thereby reducing systemic toxicity and dosing frequency. Inhalable nanomedicines provide localized delivery to the pulmonary site, enhancing the concentration of the drug at the primary site of infection. CRISPR–Cas technology is emerging as a transformative approach to disabling drug-resistant genes and enhancing diagnostic precision. HDTs, including agents like vitamin D and metformin, show potential in modulating host immune responses and enhancing pathogen clearance. Nanoparticle-based vaccines, including mRNA and antigen-conjugated platforms, aim to overcome the limitations of the BCG vaccine by enhancing antigen presentation and eliciting stronger, longer-lasting immunity. Collectively, these modalities mark a shift toward more personalized, effective, and less toxic TB therapies. However, challenges such as regulatory approval, safety, scalability, and accessibility remain. This review highlights the integrated potential of nanomedicine, gene editing, and immunomodulation to transform TB care and combat drug resistance, paving the way for more robust and durable treatment strategies.

• Publication year

  2025

• Venue

  Pharmaceutics

• Publication date

  2025-11-01

• Fields of study

  Medicine, Materials Science

• Identifiers
  DOI 10.3390/pharmaceutics17111459PMID 41304797PMCID 12655763
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Outcomes of Treating Tuberculosis Patients with Drug-Resistant Tuberculosis, Human Immunodeficiency Virus, and Nutritional Status: The Combined Impact of Triple Challenges in Rural Eastern Cape

  2025cited by this paper
• Navigating the dual burden of diabetes mellitus and tuberculosis: A comprehensive review of clinical and public health strategies.

  2025cited by this paper
• Current advancements in nanoparticles for vaccines and drug delivery for the treatment of tuberculosis.

  2025cited by this paper
• Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies.

  2025cited by this paper
• Living with Tuberculosis: A Qualitative Study of Patients’ Experiences with Disease and Treatment at the Tamale Teaching Hospital

  2025cited by this paper
• Trends and Correlations of Major Infectious Diseases in Indonesia Before and After the COVID-19 Pandemic: A Comprehensive Seven-Year Analysis (2017–2023)

  2025cited by this paper
• Predictors of therapeutic exposure and pharmacokinetic variability of second-line anti-TB drugs in MDR-TB patients: a retrospective study

  2025cited by this paper
• Analysis of The Adverse Effects of Anti-Tuberculosis Drugs (ATDs) on Patients with Tuberculosis, 2024

  2025cited by this paper
• Mapping the immunological research landscape of tuberculosis: A bibliometric review of global trends and clinical themes (2016-2025).

  2025cited by this paper
• Breaking the energy chain: importance of ATP synthase in Mycobacterium tuberculosis and its potential as a drug target.

  2025cited by this paper
• Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy

  2024cited by this paper
• Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis

  2024cited by this paper
• Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance

  2024cited by this paper
• Application of CRISPR–cas-based technology for the identification of tuberculosis, drug discovery and vaccine development

  2024cited by this paper
• Tuberculosis treatment-shortening.

  2024cited by this paper
• Unveiling the promise: Exosomes as game‐changers in anti‐infective therapy

  2024cited by this paper
• Risk factors for pulmonary tuberculosis recurrence, relapse and reinfection: a systematic review and meta-analysis

  2024cited by this paper
• Mycobacterium tuberculosis: immune response, biomarkers, and therapeutic intervention

  2024cited by this paper
• HIV–TB Coinfection: Current Therapeutic Approaches and Drug Interactions

  2024cited by this paper
• Revolutionizing Tuberculosis Management With Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas Technology: A Comprehensive Literature Review

  2024cited by this paper
• The key factors influencing tuberculosis treatment outcomes: A literature review

  2024cited by this paper
• Examining effective monotherapy hypothesis for TB therapy failure and resistance emergence.

  2024cited by this paper
• A lipid nanoparticle-mRNA vaccine provides potent immunogenicity and protection against Mycobacterium tuberculosis

  2024cited by this paper
• Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review

  2024cited by this paper
• Ending tuberculosis: challenges and opportunities

  2024cited by this paper
• Encapsulation of Rifampicin in Solid Lipid Nanoparticles by Microwave‐Assisted Microemulsion Method

  2024cited by this paper
• Early detection of tuberculosis: a systematic review

  2024cited by this paper
• Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions

  2024cited by this paper
• Factors affecting ability of TB patients to follow treatment guidelines – applying a capability approach

  2023cited by this paper
• Advanced drug delivery and therapeutic strategies for tuberculosis treatment

  2023cited by this paper
• Review of inhalable nanoparticles for the pulmonary delivery of anti-tuberculosis drugs

  2023influential reference
• Recent Updates in Inhalable Drug Delivery System against Various Pulmonary Diseases: Challenges and Future Perspectives.

  2023cited by this paper
• Micro and nano-carriers-based pulmonary drug delivery system: Their current updates, challenges, and limitations – A review

  2023cited by this paper
• Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies

  2023cited by this paper
• The TB Vaccine Accelerator Council: harnessing the power of vaccines to end the tuberculosis epidemic.

  2023cited by this paper
• Side Effects of TB Therapy and Recent Therapeutic Approaches for Tuberculosis Management

  2023cited by this paper
• Metformin has immunomodulatory effects which support its potential use as adjunctive therapy in tuberculosis.

  2023cited by this paper
• Human Mesenchymal Stem Cell‐Derived Miniature Joint System for Disease Modeling and Drug Testing

  2022cited by this paper
• Nanotechnology and tuberculosis: An old disease with new treatment strategies.

  2022cited by this paper
• A multidimensional approach to the elimination of tuberculosis

  2022cited by this paper
• Improving Tuberculosis Medication Adherence: The Potential of Integrating Digital Technology and Health Belief Model

  2022cited by this paper
• Analysing the Efficiency of Health Systems: A Systematic Review of the Literature

  2022cited by this paper
• Advances in the design of combination therapies for the treatment of tuberculosis

  2022cited by this paper
• CRISPR-Based Diagnostics: A Potential Tool to Address the Diagnostic Challenges of Tuberculosis

  2022cited by this paper
• Nanomaterials in tuberculosis DNA vaccine delivery: historical perspective and current landscape

  2022cited by this paper
• Recent developments, challenges and future prospects in advanced drug delivery systems in the management of tuberculosis

  2022cited by this paper
• In the Thick of It: Formation of the Tuberculous Granuloma and Its Effects on Host and Therapeutic Responses

  2022cited by this paper
• Assessment of medicine stock-outs challenges in public health services

  2022cited by this paper
• Macrophage membrane coated nanoparticles: a biomimetic approach for enhanced and targeted delivery.

  2022cited by this paper
• Host-Directed Therapies for Tuberculosis

  2022cited by this paper
• Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches.

  2021cited by this paper
• The contribution of microfluidics to the fight against tuberculosis

  2021cited by this paper
• OUP accepted manuscript

  2021cited by this paper
• Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis

  2021cited by this paper
• Utilization of CRISPR interference to investigate the contribution of genes to pathogenesis in a macrophage model of Mycobacterium tuberculosis infection.

  2021cited by this paper
• Barriers and strategies to successful tuberculosis treatment in a high-burden tuberculosis setting: a qualitative study from the patient’s perspective

  2021cited by this paper
• Autophagy Induction as a Host-Directed Therapeutic Strategy against Mycobacterium tuberculosis Infection

  2021cited by this paper
• Host‐directed therapy to combat mycobacterial infections

  2021cited by this paper
• Nanocarrier-Based Approaches for the Efficient Delivery of Anti-Tubercular Drugs and Vaccines for Management of Tuberculosis

  2021cited by this paper
• Pretomanid for the treatment of pulmonary tuberculosis.

  2020cited by this paper
• Protective effects of pharmacological agents against aminoglycoside-induced nephrotoxicity: A systematic review

  2020cited by this paper
• Liposomes For Antibiotic Encapsulation and Delivery.

  2020cited by this paper
• New tuberculosis drug targets, their inhibitors and potential therapeutic impact.

  2020cited by this paper
• Tuberculosis vaccine: A journey from BCG to present.

  2020cited by this paper
• A Modular Microscale Granuloma Model for Immune-Microenvironment Signaling Studies in vitro

  2020cited by this paper
• Drug-Resistant Tuberculosis 2020: Where We Stand

  2020cited by this paper
• Advancement in Nanogel formulations provides controlled drug release.

  2020cited by this paper
• The thick waxy coat of mycobacteria, a protective layer against antibiotics and the host's immune system

  2020cited by this paper
• Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis

  2020cited by this paper
• Factors Influencing Patient Adherence to Tuberculosis Treatment in Ethiopia: A Literature Review

  2020cited by this paper
• Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections

  2020cited by this paper
• Next‐generation Theranostics: Functionalized Nanomaterials Enable Efficient Diagnosis and Therapy of Tuberculosis

  2020cited by this paper
• Novel Treatments against Mycobacterium tuberculosis Based on Drug Repurposing

  2020cited by this paper
• Social determinants of tuberculosis: context, framework, and the way forward to ending TB in India

  2020cited by this paper
• Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems

  2020cited by this paper
• Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

  2020cited by this paper
• Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host-Di-rected Therapies.

  2020cited by this paper
• Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine

  2019cited by this paper
• Contemporary Drug–Drug Interactions in HIV Treatment

  2019cited by this paper
• Drug Non-Adherence And Reasons Among Multidrug-Resistant Tuberculosis Patients In Guizhou, China: A Cross-Sectional Study

  2019cited by this paper
• The Diagnosis and Treatment of Tuberculosis.

  2019cited by this paper
• Pulmonary drug delivery systems of antibiotics for the treatment of respiratory tract infections

  2019cited by this paper
• Binding energies of the drugs capreomycin and streptomycin in complex with tuberculosis bacterial ribosome subunits.

  2019cited by this paper
• Linezolid: a review of its properties, function, and use in critical care

  2018cited by this paper
• Theranostic Nanoparticles for Tracking and Monitoring Disease State

  2018cited by this paper
• A mannose-conjugated multi-layered polymeric nanocarrier system for controlled and targeted release on alveolar macrophages

  2018cited by this paper
• Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis

  2018cited by this paper
• A new era for treatment of drug-resistant tuberculosis

  2018cited by this paper
• Antimicrobial activity and toxicity of gold nanoparticles: research progress, challenges and prospects

  2018cited by this paper
• New Ways to Treat Tuberculosis Using Dendrimers as Nanocarriers

  2018cited by this paper
• Dendrimers: A versatile nanocarrier for drug delivery and targeting

  2018cited by this paper
• Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization

  2018cited by this paper
• Remembering the Host in Tuberculosis Drug Development

  2018cited by this paper
• Modelling a Silent Epidemic: A Review of the In Vitro Models of Latent Tuberculosis

  2018cited by this paper
• Tuberculosis, social determinants and co-morbidities (including HIV).

  2017cited by this paper
• World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update

  2017cited by this paper
• Tuberculosis and its Treatment: An Overview.

  2017cited by this paper
• Nanotechnology-Based Approach in Tuberculosis Treatment

  2017cited by this paper
• What is Tuberculosis (TB)?

  2017cited by this paper
• Overview of drug-resistant tuberculosis worldwide

  2016cited by this paper

• Investigation of Potent Anti-Mycobacterium tuberculosis Agents Derived from Pyridine Derivatives Targeting the Enoyl Acyl Carrier Protein Reductase (InhA): Design, Synthesis, and Computational Analysis

  2026cites this paper
• Precision nanomedicine against pulmonary tuberculosis: the role of lipid-based drug delivery systems.

  2026cites this paper